药械

订阅

MedSci主页 / 所有栏目 / 药械

Veeda Clinical Research再次高分通过马来西亚监管机构NPRA审计

2018-10-22 美通社 美通社

VeedaclinicalResearchNPRA审计
关注

领先的独立合同研究组织(CRO) Veeda Clinical Research Pvt. Ltd.自豪宣布，其临床（Shivalik，艾哈迈达巴德）和生物分析机构（Insignia，艾哈迈达巴德）成功完成了由NPRA（马来西亚监管机构）进行的第二次审计，没有发现任何重大或关键缺陷。领先的独立合同研究组织Veeda Clinical Research Pvt. Ltd.自豪宣布，其临床（

领先的独立合同研究组织(CRO) Veeda Clinical Research Pvt. Ltd.自豪宣布，其临床（Shivalik，艾哈迈达巴德）和生物分析机构（Insignia，艾哈迈达巴德）成功完成了由NPRA（马来西亚监管机构）进行的第二次审计，没有发现任何重大或关键缺陷。


领先的独立合同研究组织Veeda Clinical Research Pvt. Ltd.自豪宣布，其临床（艾哈迈达巴德）和生物分析机构（艾哈迈达巴德）成功完成了由NPRA（马来西亚监管机构）进行的第二次审计，没有发现任何重大或关键缺陷。

这项检查是由NPRA检查人员进行的例行研究检查，目的是核查场所的合规性和了解对良好临床实践(Good Clinical Practices)原则的遵守情况。审计结果确认，Veeda CRO的活动符合标准操作程序和监管指南。

在过去的13年中，Veeda CRO成功通过了50次监管审计，其中有18次美国食品及药物管理局(USFDA)的检查是在过去24个月内成功进行，这表明了该公司对品质和监管合规的高水准承诺。

Veeda CR更加注重“一次性通过”，希望在临床研究领域创造更加光明的未来。成功完成这些检查再次为Veeda CR持续进行质量审查和采取改进措施提供了证明，这些审查和措施已纳入其工作文化。

Veeda CRO简介

Veeda CR是一家提供全方位服务的合同研究组织(CRO)，所开展的临床研究能够支持客户完成他们的临床项目。该公司能够借助身体健康的志愿者，提供药代动力学(PK)和药效动力学(PD)研究上面的专业服务；在仿制分子药物和新化学实体(NCE)领域开展病人试验；还能进行生物制药方面的研究。Veeda CR可以提供经过充分整合的一整套服务，包括中枢神经系统、肿瘤学和其它复杂治疗领域的一期至四期临床试验服务。该公司的服务还包括临床试验管理服务，涵盖病人招募和挽留、项目管理、临床监控、药物安全/药物警戒、医学事务、品质保证以及监管和医学方面的写作等领域，以便满足全球临床开发需求。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991227, encodeId=28ba199122eed, content=<a href='/topic/show?id=0c3c10146677' target=_blank style='color:#2F92EE;'>#马来西亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101466, encryptionId=0c3c10146677, topicName=马来西亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Wed Dec 26 00:48:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371570, encodeId=485013e157015, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507642, encodeId=f0d8150e642cb, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557787, encodeId=0ec6155e78765, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
    2018-12-26 jiadan198782

    #马来西亚#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1991227, encodeId=28ba199122eed, content=<a href='/topic/show?id=0c3c10146677' target=_blank style='color:#2F92EE;'>#马来西亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101466, encryptionId=0c3c10146677, topicName=马来西亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Wed Dec 26 00:48:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371570, encodeId=485013e157015, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507642, encodeId=f0d8150e642cb, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557787, encodeId=0ec6155e78765, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
    2018-10-24 wwzzly

    #监管#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1991227, encodeId=28ba199122eed, content=<a href='/topic/show?id=0c3c10146677' target=_blank style='color:#2F92EE;'>#马来西亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101466, encryptionId=0c3c10146677, topicName=马来西亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Wed Dec 26 00:48:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371570, encodeId=485013e157015, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507642, encodeId=f0d8150e642cb, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557787, encodeId=0ec6155e78765, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
    2018-10-24 zll0628

    #clinical#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1991227, encodeId=28ba199122eed, content=<a href='/topic/show?id=0c3c10146677' target=_blank style='color:#2F92EE;'>#马来西亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101466, encryptionId=0c3c10146677, topicName=马来西亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Wed Dec 26 00:48:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371570, encodeId=485013e157015, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507642, encodeId=f0d8150e642cb, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557787, encodeId=0ec6155e78765, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Wed Oct 24 01:48:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
    2018-10-24 yangshch

    #Research#

    0